Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Profound Medical Corp. (NASDAQ:PROF) will release its first quarter 2023 financial results after the market closes on May 10, 2023. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will review the financial outcomes and discuss recent business developments. Profound is known for its incision-free therapies for the ablation of diseased tissue, notably its TULSA-PRO® technology, which offers customizable, radiation-free treatments for prostate issues. The company has also commercialized Sonalleve®, a platform for treating uterine fibroids and palliative pain in bone metastases, which holds multiple regulatory approvals including FDA clearance.